33 results about "Celiac diseases" patented technology

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

Disclosed herein are formulations, substrates, and arrays. Also disclosed herein are methods for manufacturing and using the formulations, substrates, and arrays. Also disclosed are methods for identifying peptide sequences useful for diagnosis and treatment of disorders, and methods for using the peptide sequences for diagnosis and treatment of disorders, e.g., celiac disorder. In certain embodiments, substrates and arrays comprise a porous layer for synthesis and attachment of polymers or biomolecules.

A Bifidobacterium longum subsp longum produced by a method of growing the Bifidobacterium longum subsp longum in a culture medium, the culture medium containing a fructose disaccharide, FOS or combination thereof. A method for treatment or prevention of inflammatory bowel disease, celiac disease, non-celiac gluten sensitivity, gluten ataxia, dermatitis herpetiformis or wheat allergy in an individual, the method including administering a combination of (i) Bifidobacterium longum subsp longum and (ii) a fructose disaccharide, FOS or a combination thereof to the individual.

Interleukin-23 receptor (IL23R) VHH antibodies are disclosed, as well as methods of making and using the same, e.g., for treatment of IL23-mediated diseases and disorders, including, e.g., gastrointestinal-related (Gl-related) diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), a colon cancer, a small intestine cancer, a gastric cancer, an irritable bowel syndrome, a gastrointestinal ulcer, a gut-associated infection (e.g., a Salmonella infection or a Clostridium difficile infection), celiac disease, or pathogenic inflammation).

The invention discloses a phosphatidylserine modified gliadin nanoparticle as well as a preparation method and application thereof. The phosphatidylserine modified gliadin nanoparticle is of a core-shell structure, gliadin is entrapped by polylactic acid-glycolic acid copolymer to serve as a core, and a lipid composite membrane formed by phosphatidylserine and DSPE-PEG2000 is coated outside the nanoparticle. The gliadin-loaded nanoparticles modified by phosphatidylserine are used for simulating membrane signal characteristics of apoptotic bodies, enhancing recognition and uptake of the nanoparticles by macrophages and inducing tolerance phenotypic transformation of the nanoparticles, so that immune tolerance of celiac disease patients to gliadin is recovered, and the gliadin-loaded nanoparticles can be used for treating celiac disease patients. On the basis of simplifying the preparation process, the problems of unstable tolerance effect and lack of metabolic regulation in the existing nano immunotherapy are further solved. The nano-particles prepared by the technical route have good particle size distribution and stability, can effectively deliver antigens and induce immune tolerance, and are a novel convertible celiac disease treatment nano-preparation.

Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII).

Described herein are methods and compositions relating to the inhibition of bile salt hydrolase (BSH) and uses thereof.SOLUTION: Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (such as gastrointestinal infections; inflammatory bowel diseases (IBD); appendicitis; Crohn's disease (CD); ulcerative cholitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetics; hepatits; hepatic diseases (such as non-alcoholic fatty liver disease (NAFLD); non-alcoholic fat hepatits (NASH); hepatits A; hepatits B; hepatits C; autoimmune hepatits; and cirrhosis of the liver); gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcers; infectious colitis; irritable bowel syndromes; intestinal wall leakage; and cancers); Methods for treating cancer (e.g., cancer of the digestive system, liver cancer) or inflammatory diseases (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcers, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to the subject a compound represented by Formulae (I) - (XVIII).SELECTED DRAWING: None

An aspartic protease and the use of the aspartic protease in the hydrolysis of gluten. This protease can hydrolyze gluten and the gluten-derived immunogenic peptides at pH 2.0˜4.0. Also provided are methods for the production of the aspartic protease, including recombinant plasmids, transformants, and a purification method thereof; methods of using the aspartic protease to prepare drugs and oral enzyme supplements for treatment of diseases or discomforts related to gluten ingestion, such as celiac disease; and a method of using the asparic protease in food-processing process to remove or reduce gluten in foods or beverages.

Provided herein are agents and methods suitable for the treatment of inflammatory diseases of the intestine. For instance, agents and methods are provided for the treatment of inflammatory bowel disease, Crohn's disease, ulcerative colitis, Celiac disease, and colitis-associated colorectal cancer.

The present invention relates to the prophylactic and / or therapeutic treatment of a disease selected from the group consisting of long-term COVID disease, myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) disease, fibromyalgia, dementia, neoplastic disease, autoimmune disease, schizophrenia, epileptic seizure disease, excessive inflammatory disease, chronic inflammatory bowel disease, rheumatic disease, obesity, and the like. Hyperuricemia, diabetes (IDDM / NIDDM), acute viral diseases, amyotrophic lateral sclerosis (ALS), bronchial asthma, atopic allergic disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, autoimmune diseases / antibody-related diseases, bipolar affective disorders, celiac disease (CD), chronic obstructive pulmonary disease (COPD), and the like. Chronic inflammatory bowel disease (CED) (i.e. Crohn's disease, ulcerative colitis), cystic fibrosis / cystic fibrosis, depression, endometriosis, polycystic ovarian syndrome, eating disorders, anxiety disorders, addiction disorders, frontotemporal dementia (Pickk's disease), Graves's disease (GD), generalized cardiovascular diseases, Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosis (MS), and the like. Muscular dystrophy, neurodermatitis, peripheral arterial occlusion disease (PAOD), pneumonia, generalized post-vaccination syndrome and vaccine damage, post-viral infection syndrome, psoriasis, pulmonary arterial hypertension, restless leg syndrome, restrictive pulmonary disease, rheumatoid arthritis (RA), division affective disorder, sepsis, sicca syndrome (SS), scleroderma, and the like. Systemic lupus erythematosus (SLE) and unsatisfactory fertility desires, using an active agent having a nicotinic acetylcholinergic agonist and / or an active agent having a muscarinic acetylcholinergic agonist and / or a muscarinic acetylcholinergic antagonist. This provides a very effective prophylactic and / or therapeutic treatment for these diseases. This prevention or treatment is also readily tolerable, cost effective and easy to apply.

The present invention relates to sirtuin 6 (SIRT6) modulator IMU-856 or a pharmaceutically acceptable salt or solvate thereof for use in a method of preventing, treating or ameliorating an inflammatory condition, such as a gastrointestinal tract disease such as celiac disease (CelD), comprising administering to a human a therapeutically effective amount of said SIRT6 modulator, and to a corresponding method of preventing, treating or ameliorating an inflammatory condition.

The application belongs to the field of medicine, and relates to a pyrimidine carboxamide compound and a preparation method and application thereof.The pyrimidine carboxamide compound has the following structure: the compound is verified by experiments to have significant anti-inflammatory activity. ELISA experiments and qPCRs prove that the compound can significantly inhibit the expression of IFN-beta and other inflammatory factors, and promote the release of inflammatory factors. The compound can be used for preparing a medicine for treating inflammation, in particular, for treating inflammatory bowel disease, celiac disease, colitis, Crohn's disease and the like, and has potential medical value and important medical prospects.

A de-epitoped alpha gliadin is provided. Methods of generating same and uses thereof are also provided.

The present application relates to a method for increasing tolerance to gliadin in a subject, in particular in a subject suffering from celiac disease, comprising repeatedly administered a polypeptide construct comprising several epitopes from gliadin isoforms preferably by epicutaneous route. The present application also relates to the polypeptide construct per se and a skin patch containing the same.

The present invention relates generally to the field of antigen binding proteins such as antibodies, in particular those which bind to HLA-DQ2.5:DQ2.5-glia-α1a, or which bind to HLA-DQ2.5:DQ2.5-glia-α2. The invention further relates to compositions and immunoconjugates comprising such antibodies and to methods of producing such antibodies. The invention also relates to methods and uses which employ such antibodies, for example in the treatment of celiac disease.

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is the CXCR3 antagonist 1-{(R)-2-(2-Hydroxy-ethyl)-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl}-2-(3-methyl-[1,2,4]triazol-1-yl)-ethanone, or a pharmaceutically acceptable salt thereof, and a second active ingredient which is an anti-CD3 monoclonal antibody (mAb); and to the use of the pharmaceutical combination in the prevention, prophylaxis and / or treatment of (auto-)immune / inflammatory mediated disorders, including type 1 diabetes (T1D) (especially autoimmune T1D), multiple sclerosis, organ transplant rejection (especially renal and heart allograft rejection), thyroid eye disease, rheumatoid arthritis, ulcerative colitis, crohn's disease, celiac disease, atherosclerosis, psoriasis, lung inflammation, and psoriatic arthritis.

Provided is a method of inhibiting an immune response in a subject with celiac disease or a subject with HLA-DQ2.5 or HLA-DQ8 haplotype alleles, the method comprising administering a CD122 binding agent to the subject.

The present application relates to a method for increasing tolerance to gliadin in a subject, in particular in a subject suffering from celiac disease, comprising repeatedly administered a polypeptide construct comprising several epitopes from gliadin isoforms preferably by epicutaneous route. The present application also relates to the polypeptide construct per se and a skin patch containing the same.

The present invention provides compositions and methods for treating autoimmune conditions. [Solution] The present invention relates to a composition comprising nanoparticles associated with multiple tolerogenic antigens (e.g., 1 to 30 tolerogenic 5 antigens per nanoparticle) in a manner that promotes potent immune tolerance upon administration to a subject (e.g., a human subject suffering from or at risk of suffering from an autoimmune disorder (e.g., MS or celiac disease)). The present invention further relates to a method for utilizing the above nanoparticles to treat an autoimmune disorder (e.g., MS or celiac disease).

Disclosed herein are formulations, substrates, and arrays. Also disclosed herein are methods for manufacturing and using the formulations, substrates, and arrays. Also disclosed are methods for identifying peptide sequences useful for diagnosis and treatment of disorders, and methods for using the peptide sequences for diagnosis and treatment of disorders, e.g., celiac disorder. In certain embodiments, substrates and arrays comprise a porous layer for synthesis and attachment of polymers or biomolecules.

The present invention provides systemic formulations, particularly oral formulations, for use in the prevention and / or treatment of celiac disease. [Solution] A systemic formulation is provided comprising a compound of formula I, or its enantiomer, solvate, hydrate, or pharmaceutically acceptable salt, wherein the systemic formulation comprises at least one acidifying agent. TIFF2026086651000024.tif47170

The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., Celiac disease. Furthermore, a set of novel biomarkers for Celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers.

The present disclosure relates to sequence selective deoxyribonucleic acid (DNA) binding compounds comprising a polyamide moiety configured to bind a DNA sequence. The invention also relates pharmaceutical compositions comprising the compounds, and methods of using the compounds for restoring expression of autoimmune regulator (AIRE) gene. The invention further relates to pharmaceutical compositions comprising the compounds, and methods of using the compounds for and treating an autoimmune disease (e.g., Addison disease, Celiac disease, dermatomyositis. Graves disease, Hashimoto thyroiditis, inflammatory bowel disease, multiple sclerosis (MS), myasthenia gravis, pernicious anemia, reactive arthritis, Sjogren syndrome, systemic lupus erythematosus, and type I diabetes). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.

The invention provides a method for treating oats. The present invention relates to a process for the preparation of oat granules, comprising the following steps: a) providing oat granules, b) heat treating the oat granules at a temperature of 95-100 DEG C, c) processing the oat granules in a disc mill to obtain ground oat granules, d) sizing the ground oat granules to obtain at least one finer product component and at least one coarser product component. The technical result consists in providing an oat flour having a low alcohol soluble glutenin content, in particular a compound that causes dietary sensitivity and disorders in patients diagnosed with celiac disease. The method is suitable for large-scale production, especially because the separation is carried out in a dry state. All the oat hulls can be recycled and used for different purposes, so that any part of the oat hulls does not need to be discarded.

The application discloses application of Bacteroides fragilis in preparation of products for preventing and / or treating celiac disease, and a composition containing Bacteroides fragilis for treating and / or preventing celiac disease. The application proves through a large number of experiments that Bacteroides fragilis, especially Bacteroides fragilis ZY-312 with a preservation number of CGMCC No. 10685, can increase the expression of tight junction related proteins, improve intestinal barrier permeability, down-regulate TTG-IgA antibodies and pro-inflammatory factors IFN gamma and IL-15, reduce inflammation, and effectively prevent and treat celiac disease.

This invention belongs to the field of food processing technology, specifically relating to a gluten-free corn cake and its preparation method. The corn cake is made from the following ingredients: whole corn flour, edible tapioca starch, raw soybean flour, trehalose, yeast, baking soda, and water. The preparation method includes mixing the flours, making a paste, fermentation, tunnel microwave cooking, and cooling and packaging. This invention uses whole corn flour, maximizing the retention of dietary fiber, vitamins, and minerals in corn. Combined with microwave instant cooking technology, the resulting corn cake has a delicate, soft, and elastic texture, a rich flavor, and a uniform and stable structure. The resulting corn cake has extremely low gluten content, meeting gluten-free food standards, and is safe for consumption by people with celiac disease or non-celiac gluten-sensitive individuals. It combines the advantages of complete nutrition, high palatability, and industrialized production, effectively solving the problems of traditional gluten-free staple foods such as limited nutrition, coarse texture, and low processing efficiency.

The invention relates to a primer probe combination and a kit for genetic typing detection of a celiac disease susceptibility gene HLA-DQ2 / -DQ8, and belongs to the field of biomedicine clinical molecular detection. The primer probe for genetic typing detection of the celiac disease susceptibility gene HLA-DQ2 / -DQ8 disclosed by the invention comprises 16 specific primers and corresponding probes which are distributed in three reaction holes. The invention also provides a kit containing the primer and probe combination for genetic typing detection of the celiac disease susceptibility gene HLA-DQ2 / -DQ8. The invention further provides a kit containing the primer and probe combination for genetic typing detection of the celiac disease susceptibility gene HLA-DQ2 / -DQ8. According to the invention, different allele site specific primers and probes of HLA-DQA1 / -DQB1, which are designed by combining ARMS with an allele specific base method, are adopted, so that the specificity and the accuracy are higher; according to the present invention, the celiac disease susceptibility gene HLA-DQ2 / -DQ8 genotyping can be obtained through one experiment, wherein the celiac disease susceptibility gene HLA-DQ2 / -DQ8 genotyping comprises DQ2.5 (DQA1 * 0501 / DQB1 * 0201), DQ2.2 (DQA1 * 0201 / DQB1 * 0202) and HLA-DQ8 (DQA1 * 0301 / DQB1 * 0302); according to the kit, all celiac disease susceptibility gene HLA-DQ2 / -DQ8 genotypes can be detected only through three reaction holes, and the kit is simple, convenient and efficient.

The invention relates to cell-assembled matrices, which resemble the endomysium and which are not taken from animal or human tissue, and which comprise antigen for celiac disease-specific antibodies; as well as solid phase matrix preparations comprising said cell-assembled matrices. Furthermore, methods for producing the cell-assembled matrix or the solid phase matrix preparation comprising the cell-assembled matrix are also disclosed. In addition, uses of the cell-assembled matrix or the solid phase matrix preparation comprising the cell-assembled matrix in a method for detecting celiac disease-specific antibodies in a sample or in a method for the in vitro diagnosis or evaluation of celiac disease in a subject are also disclosed.

A method for detecting indicators of a disease characterized by a presence of villous atrophy in images of a gastrointestinal tract (GIT), includes accessing a consecutive set of images of a portion of the GIT comprising a small bowel. Each image is associated with one or more classification scores, and each classification score is indicative of the associated image including a respective indicator of a disease characterized by the presence of villous atrophy. The method further includes selecting a subset of images from the consecutive set of images based on the one or more classification scores of each image of the consecutive set of images, identifying a segment of images which includes all of the images that show a proximal portion of the small bowel, selecting a plurality of images from the identified segment of images that represent the proximal portion of the small bowel, and displaying the selected images.